Sanofi-a Ventis Deutschland Gmbh

Hoechst Aktiengesellschaft

Sanofi

Sanofi-aventis

Aventis Pharma S.a.

Heochst Aktiengesellschaft

Gunter Muller

Stefan Petry

Norbert Tennagels

Gerhard Zoller

Hubert Heuer

Karl Schoenafinger

Hans Matter

David William Will

Karl-Heinz Baringhaus

Stefan Mullner

Anke Steinmetz

Swen Hoelder

Ingrid Sassoon

Cecile Combeau

Christine Delaisi

Georg Tschank

Paul Habermann

Ulrich Werner

Martin Bossart

Gerhard Seipke

Mark Sommerfeld

Didier Benard

Roland Kurrle

Markus Follmann

Wolfgang Konig

Dominique Tripier

Werner Sievers

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.

Insulin derivatives having an extremely delayed time-action profile

The invention relates to azole derivatives of the general formula I as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds of the invention.

Azole derivatives in the form of lipase and phospholipase inhibitors

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.

The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.

Diacyl indazole derivatives as lipase and phospholipase inhibitors

The present invention relates to azolopyridin-3-one derivatives of the general formula I with the meanings indicated in the description, their pharmaceutically usable salts and their use as medicinal substances. 

Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases

The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs. 

Indazole derivatives as inhibitors of hormone sensitive lipase

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

The present invention relates to imidazopyridin-2-one derivatives of the formula I with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments. 

Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

Disclosed are novel compound of formula I, As defined herein and their use as pharmaceutically active compounds for reducing blood glucose, and/or treating one or more of type II diabetes, disturbances of lipid and carbohydrate metabolism, arteriosclerotic manifestations, and insulin resistance.

Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use

The invention relates to a fluidized-bed scrubber containing fluidizing bodies for purifying gases and to processes for its operation. The invention enables the fluidized-bed scrubber to be dimensioned, and the processes to be carried out, in such a manner that the number of fluidizing bodies is minimized and as much energy as possible is saved, without this decreasing the purifying efficiency.

Column and processes for purifying solvent-containing gases

Phosphoinositol-glycan-peptide with insulin-like action Phosphoinositol-glycan-peptides obtainable by cleavage of adenosine 3',5'-cyclic monophosphate-binding protein, which contain glucosamine, galactose, mannose, inositol, phosphoric acid, ethanolamine and a peptide with the sequence Asx-Cys-Tyr, the preparation and use thereof for the treatment of diabetes mellitus and non-insulin-dependent diabetes are described.

Phosphoinositol-glycan-peptide with insulin-like action

A method for the treatment of diabetes mellitus or non-insulin-dependent diabetes comprising at least one peptide selected from the group consisting of Tyr-Gln-Leu-Glu-Asn-Tar-Cys-Asn, Acetyl-Leu-Glu-Asn-Tar-Cys-Asn OH, Asn-Tar-Cys-Asn, or a peptide of the formula

Growing community of inventors

Sulzbach, Germany

Gunter Muller